Acrivon Therapeutics (ACRV) Stock: Buy, Sell, or Hold?
ACRV - Acrivon Therapeutics, Inc. Common Stock
$2.00
-0.04 (-1.96%)
âŧ
5d:
-2.91%
30d:
+16.28%
90d:
+38.89%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ACRV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ACRV is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ACRV is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ACRV is currently trading at $2.00, which is considered fair relative to its 30-day fair value range of $1.79 to $2.20.
Technical Outlook: Technically, ACRV is in a uptrend. The price is currently testing key support at $1.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACRV scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+475.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACRV is in a uptrend. The price is currently testing key support at $1.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACRV scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+475.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.79 -
$2.20
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 475.0% below Wall St target ($11.50)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.79 -
$2.20
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.95
Resistance Level
$2.20
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.19
Wall Street Target
$11.50
(+475.0%)
Share & Embed Analysis
Last updated: September 12, 2026 3:25 AM ET
Data refreshes hourly during market hours. Next update: 4:25 AM
Data refreshes hourly during market hours. Next update: 4:25 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 48 HOLD |
